1. Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study. Issue 2 (22nd February 2020) Authors: Lawitz, Eric; Poordad, Fred; Gutierrez, Julio A.; Beumont, Maria; Beets, Greet; Vandevoorde, Ann; Remoortere, Pieter Van; Luo, Donghan; Vijgen, Leen; Eygen, Veerle Van; Gamil, Mohamed Journal: Health science reports Issue: Volume 3:Issue 2(2020) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗